The US-based pharmaceutical company has appealed against the 5 April order that dismissed its plea for limiting Glenmark Pharmaceuticals from producing and marketing drugs Zita and Zita-Met indicated for type-2 diabetes treatment.
In its dismissed plea, MSD said that Glenmark had violated its intellectual property right over Januvia and Janumet drugs by launching their own drugs containing the same salts, according to the Press Trust of India.
MSD had said that it had invented sitagliptin salt, which is used in the anti-diabetes drugs, and has patented the molecule.